Catalyst
Slingshot members are tracking this event:
Prothena (PRTA) Phase 2 MAD Study testing PRX002 and RG7935 in Parkinson's Disease set for 2017 Q2 initiation
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PRTA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jul 05, 2017
Occurred Source:
http://ir.prothena.com/releasedetail.cfm?ReleaseID=1032188
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Parkinson’s Disease, Prx002, Rg7935, Mad Clinical Trial, Phase 2
